D. Moller

发表

Alternatively spliced variants of the insulin receptor protein. Expression in normal and diabetic human tissues.

J. Flier, H. Benecke, D. Moller, 1992, The Journal of clinical investigation.

Differential regulation of MAP kinase, p70S6K, and Akt by contraction and insulin in rat skeletal muscle.

D. Moller, D. J. Sherwood, S. Dufresne, 1999, American journal of physiology. Endocrinology and metabolism.

Differential regulation of MAP kinase, p70(S6K), and Akt by contraction and insulin in rat skeletal muscle.

D. Moller, D. J. Sherwood, S. Dufresne, 1999, The American journal of physiology.

Role of AMP-activated protein kinase in mechanism of metformin action.

Margaret S. Wu, G. Zhou, N. Fujii, 2001, The Journal of clinical investigation.

A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth.

E. Fleck, J. Berger, D. Moller, 2003, European journal of pharmacology.

Detection of insulin receptor tyrosine kinase activity using time-resolved fluorescence energy transfer technology.

D. Moller, D. E. Biazzo-Ashnault, Y. W. Park, 2001, Analytical biochemistry.

Insulin- and Mitogen-activated Protein Kinase-mediated Phosphorylation and Activation of Peroxisome Proliferator-activated Receptor γ*

G. Zhou, J. Berger, D. Moller, 1996, The Journal of Biological Chemistry.

The mechanisms of action of PPARs.

J. Berger, D. Moller, 2002, Annual review of medicine.

Novel 3,4-dihydroquinolin-2(1H)-one inhibitors of human glycogen phosphorylase a.

D. Moller, R. Myers, A. Ogawa, 2003, Bioorganic & medicinal chemistry letters.

Cloning and characterization of p97MAPK, a novel human homolog of rat ERK-3

J. Flier, Y. Zhao, D. Moller, 1994, Molecular and cellular biology.

A Novel Liver X Receptor Agonist Establishes Species Differences in the Regulation of Cholesterol 7α-Hydroxylase (CYP7a).

Y. Chao, D. Moller, Gaochao Zhou, 2002, Endocrinology.

A Novel Liver X Receptor Agonist Establishes Species Differences in the Regulation of Cholesterol 7α-Hydroxylase (CYP7a).

Y. Chao, D. Moller, Gaochao Zhou, 2002, Endocrinology.

Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: Evidence for an antiinflammatory role for lipoprotein lipase

D. Rader, S. Perrey, R. Zechner, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.

J. Berger, D. Moller, T. Doebber, 2005, Journal of medicinal chemistry.

Evidence Against Altered Expression of GLUT1 or GLUT4 in Skeletal Muscle of Patients With Obesity or NIDDM

J. Flier, D. Moller, B. Kahn, 1990, Diabetes.

Overexpression of Hexokinase II in Transgenic Mice

R. Printz, D. Moller, J. Ivy, 1996, The Journal of Biological Chemistry.

Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man.

J. Flier, D. Moller, A. Yokota, 1989, Molecular endocrinology.

Hyperglycemia-induced Production of Acute Phase Reactants in Adipose Tissue*

N. Barzilai, J. Berger, D. Moller, 2001, The Journal of Biological Chemistry.

Transgenic mice with muscle-specific insulin resistance develop increased adiposity, impaired glucose tolerance, and dyslipidemia.

J. Flier, D. Moller, H. Wallberg-henriksson, 1996, Endocrinology.

Analysis of the Hexokinase II Gene in Subjects With Insulin Resistance and NIDDM and Detection of a Gln142→His Substitution

I. Stratton, R. Printz, D. Moller, 1995, Diabetes.

Impaired Insulin Signaling in Skeletal Muscles from Transgenic Mice Expressing Kinase-deficient Insulin Receptors (*)

H. Benecke, D. Moller, L. Goodyear, 1995, The Journal of Biological Chemistry.

Targeted Disruption of the Tumor Necrosis Factor-α Gene: Metabolic Consequences in Obese and Nonobese Mice

Margaret S. Wu, G. Kollias, M. Pasparakis, 1997, Diabetes.

Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.

S. O’Rahilly, J. Berger, D. Moller, 2002, Endocrinology.

Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha.

B. Spiegelman, J. Berger, D. Moller, 1996, Molecular endocrinology.

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action

D. Moller, S. Bolze, M. Kergoat, 2020, bioRxiv.

Effects of exercise and insulin on mitogen-activated protein kinase signaling pathways in rat skeletal muscle.

D. Moller, D. J. Sherwood, S. Dufresne, 1996, The American journal of physiology.

Coordinate regulation of glucose transporter function, number, and gene expression by insulin and sulfonylureas in L6 rat skeletal muscle cells.

J. Flier, D. Moller, R. Smith, 1989, The Journal of clinical investigation.

Human rsk isoforms: cloning and characterization of tissue-specific expression.

D. Moller, A. Zhu, W. Tang, 1994, The American journal of physiology.

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study

K. Cusi, D. Moller, J. Dubourg, 2021, Cell reports. Medicine.

Potential Role of TNF-α in the Pathogenesis of Insulin Resistance and Type 2 Diabetes

D. Moller, 2000, Trends in Endocrinology & Metabolism.

Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes.

D. Moller, 2000, Trends in endocrinology and metabolism: TEM.

Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance.

D. Moller, A. Moses, L. Morrow, 1994, The Journal of clinical endocrinology and metabolism.

Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus.

J. Flier, D. Moller, A. Moses, 1995, Diabetes research and clinical practice.

Ribosomal subunit kinase-2 is required for growth factor-stimulated transcription of the c-Fos gene.

Y. Zhao, D. Moller, B. Knebel, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin

E. Fontaine, D. Moller, G. Vial, 2022, Physiological reports.

Identification and Characterization of a Major Liver Lysophosphatidylcholine Acyltransferase*

D. Bredt, M. Kowala, D. Moller, 2008, Journal of Biological Chemistry.

Identification and Characterization of a Lysophosphatidylcholine Acyltransferase That is Primarily Expressed in Metabolic Tissues

D. Bredt, M. Kowala, D. Moller, 2008 .

Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation

J. Berger, D. Moller, DE Moller, 2003, International Journal of Obesity.

Normal Insulin-Receptor cDNA Sequence in Pima Indians With NIDDM

J. Flier, D. Moller, A. Yokota, 1989, Diabetes.

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

D. Moller, N. Thornberry, S. Conarello, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Peroxisome Proliferator-Activated Receptors

D. Moller, K. Macnaul, 2003 .

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

T. Hardy, H. Fu, D. Moller, 2015, Diabetes Care.

New approaches in the treatment of type 2 diabetes.

D. Moller, B. Zhang, David E. Moller, 2000, Current opinion in chemical biology.

Insulin resistance--mechanisms, syndromes, and implications.

J. Flier, D. Moller, David E. Moller, 1991, The New England journal of medicine.

Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance.

S. O’Rahilly, J. Flier, F. Grigorescu, 1993, The Journal of clinical endocrinology and metabolism.

Biologic activities of naturally occurring human insulin receptor mutations. Evidence that metabolic effects of insulin can be mediated by a kinase-deficient insulin receptor mutant.

J. Flier, H. Benecke, D. Moller, 1991, The Journal of biological chemistry.

A naturally occurring mutation of insulin receptor alanine 1134 impairs tyrosine kinase function and is associated with dominantly inherited insulin resistance.

J. Flier, M. White, D. Moller, 1990, The Journal of biological chemistry.

A Potent Synthetic LXR Agonist Is More Effective than Cholesterol Loading at Inducing ABCA1 mRNA and Stimulating Cholesterol Efflux*

D. Moller, Gaochao Zhou, S. Wright, 2002, The Journal of Biological Chemistry.

Salicylic Acid Reverses Phorbol 12-Myristate-13-Acetate (PMA)- and Tumor Necrosis Factor α (TNFα)-induced Insulin Receptor Substrate 1 (IRS1) Serine 307 Phosphorylation and Insulin Resistance in Human Embryonic Kidney 293 (HEK293) Cells*

D. Moller, Bei B. Zhang, Franklin Liu, 2003, The Journal of Biological Chemistry.

A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects.

D. Moller, V. Ding, S. Qureshi, 2004, Diabetes.

Activation of PPARdelta alters lipid metabolism in db/db mice.

J. Auwerx, M. D. Leibowitz, D. Moller, 2000, FEBS letters.

Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression.

D. Moller, M. Wu, J. Ventre, 1998, Endocrinology.

O-Arylmandelic acids as highly selective human PPAR α/γ agonists

J. Berger, D. Moller, Gaochao Zhou, 2003 .

Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes.

Olle Ljunqvist, D. Moller, L. Goodyear, 2002, Diabetes.

Mutant insulin receptors in syndromes of insulin resistance

S. O’Rahilly, D. Moller, 1992, Clinical endocrinology.

Molecular Scanning of Insulin-Responsive Glucose Transporter (GLUT4) Gene in NIDDM Subjects

S. O’Rahilly, J. Flier, J. Buse, 1991, Diabetes.

Peroxisome Proliferator-Activated Receptor (PPAR)-α Agonism Prevents the Onset of Type 2 Diabetes in Zucker Diabetic Fatty Rats: A Comparison with PPARγ Agonism

J. Berger, D. Moller, T. Doebber, 2006 .

FGF21-based pharmacotherapy – potential utility for metabolic disorders

D. Moller, R. Gimeno, 2014, Trends in Endocrinology & Metabolism.

Detection of Mutations in Insulin-Receptor Gene in NIDDM Patients by Analysis of Single-Stranded Conformation Polymorphisms

S. O’Rahilly, J. Flier, R. Turner, 1991, Diabetes.

Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy

D. Moller, T. Nagaraja, Jaspreet Singh, 2022, The Journal of Pharmacology and Experimental Therapeutics.

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.

K. Cusi, D. Moller, N. Alkhouri, 2021, The lancet. Gastroenterology & hepatology.

A point mutation in transthyretin increases affinity for thyroxine and produces euthyroid hyperthyroxinemia.

J. Haddow, J. Liepnieks, M. Benson, 1990, The Journal of clinical investigation.

Examination of the phosphoenolpyruvate carboxykinase gene promoter in patients with noninsulin-dependent diabetes mellitus.

J. Flier, R. Printz, R. O’Brien, 1996, The Journal of clinical endocrinology and metabolism.

Insulin receptor and insulin-responsive glucose transporter (GLUT 4) mutations and polymorphisms in a welsh type 2 (non-insulin-dependent) diabetic population

S. O’Rahilly, J. Flier, D. Moller, 1992, Diabetologia.

Ligand-binding properties of the two isoforms of the human insulin receptor.

J. Flier, B. Ransil, Y. Yamaguchi, 1993, Endocrinology.

Binding of human, porcine and bovine insulin to insulin receptors from human brain, muscle and adipocytes and to expressed recombinant alternatively spliced insulin receptor isoforms

H. Klein, U. Missler, D. Moller, 1995, Diabetologia.

Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2.

M. D. Leibowitz, J. Berger, D. Moller, 1996, Biochemical and biophysical research communications.

Secreted PCSK 9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis

Y. Qian, D. Moller, Xiliang Wang, 2007 .

Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity

A. Deshmukh, D. Moller, J. Zierath, 2011, Diabetes/metabolism research and reviews.

Two Naturally Occurring Mutant Insulin Receptors Phosphorylate Insulin Receptor Substrate-1 (IRS-1) but Fail to Mediate the Biological Effects of Insulin

S. O’Rahilly, D. Moller, A. Krook, 1996, The Journal of Biological Chemistry.

Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.

R. Thieringer, J. Berger, D. Moller, 2001, The Journal of biological chemistry.

Differential Gene Regulation in Human Versus Rodent Hepatocytes by Peroxisome Proliferator-activated Receptor (PPAR) α

J. Berger, D. Moller, Gaochao Zhou, 2001, The Journal of Biological Chemistry.

Functional properties of a naturally occurring Trp1200----Ser1200 mutation of the insulin receptor.

J. Flier, D. Moller, F. Ginsberg-Fellner, 1990, Molecular endocrinology.

Inhibitors of insulin receptor tyrosine kinase in fibroblasts from diverse patients with impaired insulin action: evidence for a novel mechanism of postreceptor insulin resistance.

G. Reaven, D. Moller, I. Goldfine, 1993, The Journal of clinical endocrinology and metabolism.

AGPAT6 Is a Novel Microsomal Glycerol-3-phosphate Acyltransferase*

D. Bredt, S. Young, Y. Qian, 2008, Journal of Biological Chemistry.

Both coactivator LXXLL motif-dependent and -independent interactions are required for peroxisome proliferator-activated receptor gamma (PPARgamma) function.

Y. Li, G. Zhou, D. Moller, 2000, The Journal of biological chemistry.

Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis

D. Moller, D. Carling, M. Foretz, 2021, Hepatology communications.

Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists.

D. Gerhold, D. Holder, J. Berger, 2002, Endocrinology.

Novel 3,4‐Dihydroquinolin‐2(1H)‐one Inhibitors of Human Glycogen Phosphorylase a.

D. Moller, R. Myers, A. Ogawa, 2004 .

Selective PPARgamma modulators with improved pharmacological profiles.

Margaret S. Wu, J. Berger, D. Moller, 2005, Bioorganic & medicinal chemistry letters.

Benzoyl 2-methyl indoles as selective PPARgamma modulators.

J. Berger, D. Moller, T. Doebber, 2005, Bioorganic & medicinal chemistry letters.

Loss of insulin binding and insulin receptor mRNA in a transformed human fetal fibroblast cell line.

J. Flier, D. Moller, K. Mountjoy, 1990, Biochemical and biophysical research communications.

Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249

T. Hardy, H. Fu, D. Moller, 2016, Diabetes Care.

Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats

D. Moller, S. Bolze, M. Kergoat, 2020, Endocrinology, diabetes & metabolism.

Regulation of insulin signal transduction pathway by a small-molecule insulin receptor activator.

D. Moller, D. E. Biazzo-Ashnault, V. Ding, 2002, The Biochemical journal.

The stimulation of pp42mapkinase by insulin does not correlate with its metabolic actions in cells overexpressing mutant insulin receptors.

J. Flier, A. Saltiel, D. Moller, 1993, Biochemical and biophysical research communications.

Relation between the insulin receptor number in cells, autophosphorylation and insulin-stimulated Ras.GTP formation.

J. Flier, R. Medema, J. Bos, 1992, The Journal of biological chemistry.

Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation.

R G Smith, Y. Li, G. Zhou, 2000, Journal of molecular biology.

Comment on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 2013;62:2595–2604

R. Heine, H. Fu, D. Kendall, 2013, Diabetes.

Insulin Stimulation of Mitogen-activated Protein Kinase, p90rsk, and p70 S6 Kinase in Skeletal Muscle of Normal and Insulin-resistant Mice

Y. Le Marchand-Brustel, D. Moller, P. Chang, 1995, The Journal of Biological Chemistry.

Sex hormone-binding globulin mediates prostate androgen receptor action via a novel signaling pathway.

D. Moller, W. Rosner, L. Rhodes, 1998, Endocrinology.

Autoantibodies to the insulin receptor as a cause of autoimmune hypoglycemia in systemic lupus erythematosus.

D. Moller, S. Taylor, R. Ratner, 1988, American Journal of Medicine.

Therapeutic potential of deuterium‐stabilized (R)‐pioglitazone—PXL065—for X‐linked adrenoleukodystrophy

D. Moller, V. Jacques, T. Nagaraja, 2022, Journal of inherited metabolic disease.

Design and Synthesis of α-Aryloxyphenylacetic Acid Derivatives: A Novel Class of PPARα/γ Dual Agonists with Potent Antihyperglycemic and Lipid Modulating Activity

Y. Chao, J. Berger, D. Moller, 2005 .

Regulation of acetyl coenzyme-A carboxylase gene in a transgenic animal model.

D. Moller, K. Kim, D. Ekhterae, 1996, Biochemical and biophysical research communications.

Insulin Stimulation of Mitogen-activated Protein Kinase, p90 rsk , and p70 S6 Kinase in Skeletal Muscle of Normal and Insulin-resistant Mice IMPLICATIONS FOR THE REGULATION OF GLYCOGEN SYNTHASE*

D. Moller, Y. Marchand-Brustel, P. Chang, 1995 .

Metabolic syndrome: a clinical and molecular perspective.

D. Moller, K. Kaufman, 2005, Annual review of medicine.

The basal SAR of a novel insulin receptor activator.

D. Moller, B. Zhang, D. Szalkowski, 2000, Bioorganic & medicinal chemistry letters.

Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.

J. Berger, D. Moller, Gaochao Zhou, 2005, Journal of medicinal chemistry.

Hemarthrosis and idiopathic thrombocytopenic purpura.

D. Moller, K. Goldstein, 1987, Journal of Rheumatology.

New drug targets for type 2 diabetes and the metabolic syndrome

D. Moller, David E. Moller, 2001, Nature.

Severe Insulin-Resistance Hyperandrogenic Syndromes

D. Moller, A. Vidal-Puig, R. Azziz, 2006 .

Functional Antagonism between CCAAT/Enhancer Binding Protein-α and Peroxisome Proliferator-activated Receptor-γ on the Leptin Promoter*

B. Spiegelman, B. Lowell, D. Moller, 1997, The Journal of Biological Chemistry.

Discovery of a potent, highly selective, and orally efficacious small-molecule activator of the insulin receptor.

D. Moller, V. Ding, B. Zhang, 2000, Journal of medicinal chemistry.

Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer.

G. Zhou, H. Wilkinson, J. Hermes, 1998, Molecular endocrinology.

Discovery of a small molecule insulin mimetic with antidiabetic activity in mice.

R G Smith, D. Moller, J. Zierath, 1999, Science.

(2R)-2-methylchromane-2-carboxylic acids: discovery of selective PPARalpha agonists as hypolipidemic agents.

J. Berger, D. Moller, S. Wright, 2005, Bioorganic & medicinal chemistry letters.

(2R)-2-Ethylchromane-2-carboxylic Acids: Discovery of Novel PPARα/γ Dual Agonists as Antihyperglycemic and Hypolipidemic Agents

Margaret S. Wu, Y. Chao, J. Berger, 2004 .

Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes

Yue Feng, Yun-ping Zhou, D. Moller, 2006, Diabetes.

Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome

D. Moller, A. Kanatani, Jun Kusunoki, 2006, Endocrine.

New Obesity Targets: Molecular-Genetic and Transgenic Approaches

D. Moller, L. Ploeg, 2000 .

MK-0767, a novel dual PPARα/γ agonist, displays robust antihyperglycemic and hypolipidemic activities

Margaret S. Wu, Y. Chao, J. Berger, 2004 .

Both Coactivator LXXLL Motif-dependent and -independent Interactions Are Required for Peroxisome Proliferator-activated Receptor γ (PPARγ) Function*

Bruce A. Johnson, D. Moller, Gaochao Zhou, 2000, The Journal of Biological Chemistry.

Detection of an alteration in the insulin-receptor gene in a patient with insulin resistance, acanthosis nigricans, and the polycystic ovary syndrome (type A insulin resistance).

J. Flier, D. Moller, Jeffrey S. Flier, 1988, The New England journal of medicine.

Peroxisome proliferator-activated receptor gamma agonists inhibit adipocyte expression of alpha1-acid glycoprotein.

J. Berger, D. Moller, P. Scherer, 2007, Cell biology international.

Lessons Learned from Clinical and Basic Research Applied to the Study of Patients with Severe Insulin Resistance

H. Benecke, D. Moller, 1997 .

Benzoyl 2-methyl indoles as selective PPARγ modulators

Joel P. Berger, J. Berger, D. Moller, 2005 .

Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.

Bruce A. Johnson, J. Berger, D. Moller, 2003, Molecular endocrinology.

Ansuman Bagchi, Alex Elbrecht, Arthur Fridman, 2022 .

Peroxisome Proliferator-activated Receptor-γ Ligands Inhibit Adipocyte 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Activity*

R. Thieringer, J. Berger, D. Moller, 2001, The Journal of Biological Chemistry.

Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes.

D. Moller, D. Greene, 2001, Advances in protein chemistry.

A PPARγ mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus

S. A. Parent, M. D. Leibowitz, J. Capone, 2000, Molecular and Cellular Endocrinology.

Activation of Peroxisome Proliferator-Activated Receptor γ Does Not Inhibit IL-6 or TNF-α Responses of Macrophages to Lipopolysaccharide In Vitro or In Vivo

R. Thieringer, J. Berger, D. Moller, 2000, The Journal of Immunology.

L-764406 Is a Partial Agonist of Human Peroxisome Proliferator-activated Receptor γ

J. Berger, D. Moller, Gaochao Zhou, 1999, The Journal of Biological Chemistry.

Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects*

Margaret S. Wu, Y. Li, M. D. Leibowitz, 1999, The Journal of Biological Chemistry.

Role of Skeletal Muscle in Thiazolidinedione Insulin Sensitizer ( PPAR g Agonist ) Action

Margaret S. Wu, J. Berger, D. Moller, 1998 .

Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.

B. Spiegelman, M. Jimenez-Linan, B. Lowell, 1996, The Journal of clinical investigation.

Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ1 and γ2

M. D. Leibowitz, J. Berger, D. Moller, 1996 .

Induction of Adipocyte Complement-related Protein of 30 Kilodaltons by Ppar␥ Agonists: a Potential Mechanism of Insulin Sensitization

S. O’Rahilly, J. Berger, D. Moller, 2022 .

Candidate Genes for Insulin Resistance

D. Moller, A. Vidal-Puig, Christian Bjørbæk, 1996, Diabetes Care.

Perspectives in Diabetes Transgenic Approaches to the Pathogenesis of NIDDM

D. Moller, 2010 .

Transgenic approaches to the pathogenesis of NIDDM

D. Moller, 1994, Diabetes.

Muscle-Specific Expression of Human Insulin Receptor in Transgenic Mice

H. Klein, K. Siddle, J. Flier, 1993, Diabetes.

Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese hamster ovary cells.

J. Flier, J. Backer, Y. Yamaguchi, 1991, Endocrinology.

Fibroblast growth factor 21 corrects obesity in mice.

D. Moller, Yanyun Chen, T. Coşkun, 2008, Endocrinology.

Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta.

J. Morrow, Rajnish A. Gupta, S. Dey, 1999, Genes & development.

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.

H. Fu, D. Moller, J. Chien, 2013, Cell metabolism.

RSK3 encodes a novel pp90rsk isoform with a unique N-terminal sequence: growth factor-stimulated kinase function and nuclear translocation

S. Weremowicz, C. Morton, Y. Zhao, 1995, Molecular and cellular biology.

Comparative sensitivity of alternative single-strand conformation polymorphism (SSCP) methods.

D. Moller, A. Vidal-Puig, A Vidal-Puig, 1994, BioTechniques.

Evidence for Peroxisome Proliferator-Activated Receptor (PPAR)α-Independent Peroxisome Proliferation: Effects of PPARγ/δ-Specific Agonists in PPARα-Null Mice

Margaret S. Wu, Frank J. Gonzalez, John Ventre, 2000 .

Design and synthesis of potent and subtype-selective PPARα agonists

J. Berger, D. Moller, S. Wright, 2006 .

Increased amounts of farnesylated p21Ras in tissues of hyperinsulinaemic animals

D. Moller, N. Ruderman, J. Ivy, 1999, Diabetologia.

Regulation and Interaction of pp90rsk Isoforms with Mitogen-activated Protein Kinases*

D. Moller, Christian Bjørbæk, Yi Zhao, 1996, The Journal of Biological Chemistry.

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis Published, JLR Papers in Press, April 20, 2007.

Y. Qian, D. Moller, Xiliang Wang, 2007, Journal of Lipid Research.

Selective PPARγ modulators with improved pharmacological profiles

Margaret S. Wu, J. Berger, D. Moller, 2005 .

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

E. Fontaine, D. Moller, A. Borel, 2020, Diabetes, obesity & metabolism.

Divergent Functional Roles for p90rsk Kinase Domains (*)

D. Moller, Christian Bjørbæk, Yi Zhao, 1995, The Journal of Biological Chemistry.

Inhibition of adipocyte differentiation by HIV protease inhibitors.

J. Berger, D. Moller, B. Zhang, 1999, The Journal of clinical endocrinology and metabolism.

Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists.

Margaret S. Wu, J. Berger, D. Moller, 2002, Diabetes.

Arteriographic ablation of cervical parathyroid adenomas.

D. Moller, B. Sacks, H. Eisenberg, 1989, The Journal of clinical endocrinology and metabolism.

Amphipathic 3-Phenyl-7-propylbenzisoxazoles; human pPaR γ, δ and α agonists

Joel P. Berger, J. Berger, D. Moller, 2003 .

Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion.

M. Vance, D. Moller, A. Moses, 1989, The Journal of clinical endocrinology and metabolism.

Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.

Y. Chao, J. Berger, D. Moller, 2005, Journal of medicinal chemistry.

Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319

Christopher C. Frye, Tamer Coskun, J. M. Beals, 2013, PloS one.

Peroxisome Proliferator-Activated Receptors γ and α Mediate in Vivo Regulation of Uncoupling Protein (UCP-1, UCP-2, UCP-3) Gene Expression.

Margaret S. Wu, D. Moller, J. Ventre, 1998, Endocrinology.

A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease.

D. Moller, B. Buchholz, G. Steinberg, 2023, Kidney international.

Differential Regulation of Glucose Transport and Transporters by Glucose in Vascular Endothelial and Smooth Muscle Cells

D. Moller, N. Kaiser, E. Feener, 1993, Diabetes.

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action

D. Moller, S. Bolze, M. Kergoat, 2020, bioRxiv.

Activation of PPARδ alters lipid metabolism in db/db mice

J. Auwerx, M. D. Leibowitz, J. Berger, 2000 .

The Differential Interactions of Peroxisome Proliferator-Activated Receptor γ Ligands with Tyr473 Is a Physical Basis for Their Unique Biological Activities

J. Berger, D. Moller, J. W. Becker, 2008, Molecular Pharmacology.

Altered Extracellular Signal-Regulated Kinase Signaling and Glycogen Metabolism in Skeletal Muscle from p90 Ribosomal S6 Kinase 2 Knockout Mice

D. Moller, S. Dufresne, L. Goodyear, 2001, Molecular and Cellular Biology.

Ribosomal subunit kinasE factor-stimulated transcri

D. Moller, J. Brüning, B. Knebel, 2016 .

Metabolic disease drug discovery- "hitting the target" is easier said than done.

D. Moller, 2012, Cell metabolism.

Expression of a dominant-negative mutant human insulin receptor in the muscle of transgenic mice.

Y. Le Marchand-Brustel, H. Benecke, D. Moller, 1994, The Journal of biological chemistry.

Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.

J. Berger, D. Moller, T. Doebber, 2006, Endocrinology.

Use of homogeneous time-resolved fluorescence energy transfer in the measurement of nuclear receptor activation.

G. Zhou, J. Hermes, D. Moller, 2001, Methods.

Peroxisome proliferator‐activated receptor γ agonists inhibit adipocyte expression of α1‐acid glycoprotein

J. Berger, D. Moller, P. Scherer, 2007 .

Prevalence of Mutations in the Insulin Receptor Gene in Subjects With Features of the Type A Syndrome of Insulin Resistance

J. Flier, F. Grigorescu, D. Moller, 1994, Diabetes.

Individual and Combined Effects of Peroxisome Proliferator‐Activated Receptor α and γ Agonists, Fenofibrate and Rosiglitazone, on Biomarkers of Lipid and Glucose Metabolism in Healthy Nondiabetic Volunteers

Margaret S. Wu, J. Miller, D. Moller, 2005, Journal of clinical pharmacology.

Localization of PPARδ in murine central nervous system: expression in oligodendrocytes and neurons

C. Austin, J. Berger, D. Moller, 2003, Brain Research.

Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma an

Margaret S. Wu, Harold B Wood, Yejun Tan, 2009, Journal of medicinal chemistry.

Small-molecule insulin mimetic reduces hyperglycemia and obesity in a nongenetic mouse model of type 2 diabetes.

D. Moller, D. Szalkowski, Bei B. Zhang, 2004, Endocrinology.

A Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist Demonstrates Favorable Effects on Lipid Homeostasis

Margaret S. Wu, Y. Chao, J. Berger, 2004 .

Evaluation of PXL065 - Deuterium-Stabilized (R)-Pioglitazone in NASH Patients: a Phase 2 randomized placebo-controlled trial (DESTINY-1).

K. Cusi, P. Bedossa, D. Moller, 2023, Journal of hepatology.

5-Aryl thiazolidine-2,4-diones: Discovery of PPAR dual α/γ agonists as antidiabetic agents

J. Berger, D. Moller, T. Doebber, 2003 .

Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action.

J. Berger, D. Moller, J. Zierath, 1998, Endocrinology.

Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo.

R. Thieringer, J. Berger, D. Moller, 2000, Journal of immunology.

Phenylacetic acid derivatives as hPPAR agonists.

Margaret S. Wu, J. Berger, D. Moller, 2003, Bioorganic & medicinal chemistry letters.

5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists

J. Berger, D. Moller, T. Doebber, 2003 .

Activation of Insulin Signal Transduction Pathway and Anti-diabetic Activity of Small Molecule Insulin Receptor Activators*

D. Moller, D. E. Biazzo-Ashnault, V. Ding, 2000, The Journal of Biological Chemistry.

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249

T. Hardy, H. Fu, D. Moller, 2017, Diabetes Care.

Differential Regulation of Glucose Transport and Transporters by Glucose in Vascular Endothelial and Smooth Muscle Cells

D. Moller, N. Kaiser, E. Feener, 1993, Diabetes.

Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization.

S. O’Rahilly, J. Berger, D. Moller, 2002, Endocrinology.

Coordinate regulation of glucose transporter function, number, and gene expression by insulin and sulfonylureas in L6 rat skeletal muscle cells.

D. Moller, P H Wang, J S Flier, 1989, The Journal of clinical investigation.

Peroxisome Proliferator-activated Receptor- g Ligands Inhibit Adipocyte 11 b -Hydroxysteroid Dehydrogenase Type 1 Expression and Activity*

R. Thieringer, J. Berger, D. Moller, 2001 .

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.

H. Fu, D. Moller, J. Chien, 2013, Cell metabolism.

Transgenic approaches to the pathogenesis of NIDDM.

D. Moller, 1995, Diabetes.

Role of Skeletal Muscle in Thiazolidinedione Insulin Sensitizer ( PPAR g Agonist ) Action

J. Berger, D. Moller, J. Zierath, 1998 .

Role of AMP-activated protein kinase in mechanism of metformin action.

Margaret S. Wu, N. Fujii, D. Moller, 2001, The Journal of clinical investigation.

5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.

J. Berger, D. Moller, T. Doebber, 2003, Bioorganic & medicinal chemistry letters.

Aryloxazolidinediones: identification of potent orally active PPAR dual α/γ agonists

J. Berger, D. Moller, T. Doebber, 2003 .

Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice.

D. Moller, F. Gonzalez, J. Ventre, 2000, Molecular pharmacology.